Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
312 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wong WL, Su X, Li X, et al. · Lancet Glob Health · 2014Meta-Analysis, Research Support, Non-U.S. Gov't
- LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.
Boyer D, Hu A, Warrow D, et al. · Retina · 2024Randomized Controlled Trial
- Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD.
Holz FG, Le Mer Y, Muqit MMK, et al. · N Engl J Med · 2026Multicenter Study, Clinical Trial
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- OCT Prognostic Biomarkers for Progression to Late Age-related Macular Degeneration: A Systematic Review and Meta-analysis.
Trinh M, Cheung R, Duong A, et al. · Ophthalmol Retina · 2024Systematic Review, Meta-Analysis
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR, Lawrenson JG · Cochrane Database Syst Rev · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
Keenan TDL, Agrón E, Keane PA, et al. · Ophthalmology · 2025Randomized Controlled Trial, Multicenter Study
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ, Westby K, Csaky KG, et al. · Ophthalmology · 2021Clinical Trial, Phase II, Clinical Trial, Phase III
- A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
Arch Ophthalmol · 2001Clinical Trial, Comparative Study
- LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS).
Jaffe GJ, Boyer D, Hu A, et al. · Retina · 2026Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy.
Yang S, Li T, Jia H, et al. · Sci Transl Med · 2022Clinical Trial, Research Support, Non-U.S. Gov't
- Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2.
Agrón E, Mares J, Clemons TE, et al. · Ophthalmology · 2021Clinical Trial, Phase III, Multicenter Study
- AGE-RELATED MACULAR DEGENERATION.
Gheorghe A, Mahdi L, Musat O · Rom J Ophthalmol · 2015Systematic Review
- Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS, Lally DR, Hsu J, et al. · Eye (Lond) · 2023Randomized Controlled Trial, Clinical Trial, Phase II
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.
Markowitz SN, Devenyi RG, Munk MR, et al. · Retina · 2020Randomized Controlled Trial
- The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A, Nanji K, Tai F, et al. · Surv Ophthalmol · 2024Meta-Analysis, Research Support, Non-U.S. Gov't
- Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ, Khanani AM, Kaiser PK, et al. · Ophthalmol Retina · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
Keenan TD, Agrón E, Domalpally A, et al. · Ophthalmology · 2018Clinical Trial, Phase III, Multicenter Study
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, et al. · Ophthalmology · 2020Clinical Trial, Phase II, Multicenter Study
- Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials.
Wang H, Zheng J, Zhang Q, et al. · Front Pharmacol · 2024Systematic Review
- Outer Retinal Tubulation in Geographic Atrophy.
Hatcher KA, Shah BK, Burch M, et al. · Ophthalmic Surg Lasers Imaging Retina · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration.
Kashani AH, Lebkowski JS, Hinton DR, et al. · Stem Cell Reports · 2022Clinical Trial, Phase I, Clinical Trial, Phase II
- Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT.
Schmidt-Erfurth U, Mai J, Reiter GS, et al. · Ophthalmology · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.
Wykoff CC, Holz FG, Chiang A, et al. · Am J Ophthalmol · 2025Clinical Trial, Phase III, Multicenter Study
- Simultaneous perception of prosthetic and natural vision in AMD patients.
Palanker D, Le Mer Y, Mohand-Said S, et al. · Nat Commun · 2022Clinical Trial, Research Support, N.I.H., Extramural
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.